ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 84 filers reported holding ORIC PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,327,998 | -20.7% | 384,793 | +1.7% | 0.69% | -15.8% |
| Q2 2023 | $2,935,003 | -6.7% | 378,222 | -31.5% | 0.82% | -15.0% |
| Q1 2023 | $3,144,969 | -4.2% | 551,749 | -1.0% | 0.96% | -2.7% |
| Q4 2022 | $3,283,263 | +200.7% | 557,430 | +63.4% | 0.99% | +136.5% |
| Q3 2022 | $1,092,000 | -33.2% | 341,182 | -6.5% | 0.42% | -41.1% |
| Q2 2022 | $1,634,000 | – | 364,741 | – | 0.71% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
| Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
| Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
| Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
| Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
| VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
| Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
| Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
| Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |